DENTSPLY International Inc.(XRAY)- NASDAQ
  • Fri, Aug. 5, 8:36 AM
    • DENTSPLY (NASDAQ:XRAY): Q2 EPS of $0.76 beats by $0.06.
    • Revenue of $1.02B (+46.1% Y/Y) misses by $10M.
    • Press Release
    | Fri, Aug. 5, 8:36 AM | 1 Comment
  • Thu, Aug. 4, 5:30 PM
    | Thu, Aug. 4, 5:30 PM | 1 Comment
  • Mon, Jun. 27, 9:54 AM
    • Dentsply Sirona (XRAY -1.5%) enters into a definitive agreement with privately held, Savion, Israel-based MIS Implants to buy all the outstanding shares of the dental implant manufacturer for $375M in cash.
    • MIS (Make It Simple), founded in 1995, sells its products in more that 65 countries worldwide.
    | Mon, Jun. 27, 9:54 AM
  • Fri, Jun. 17, 6:53 AM
    • HCA Holdings (NYSE:HCA) initiated with Market Perform rating and $88 (13% upside) price target by Sanford C. Bernstein.
    • UnitedHealth Group (NYSE:UNH) initiated with Outperform rating and $142 (2% upside) price target by Sanford C. Bernstein.
    • Cepheid (NASDAQ:CPHD) initiated with Equal Weight rating and $30 (1% upside) price target by Morgan Stanley.
    • Amsurg (NASDAQ:AMSG) initiated with Market Perform rating by Wells Fargo.
    • Cynapsus Therapeutics (NASDAQ:CYNA) initiated with Buy rating and $24 (41% upside) price target by Janney Capital.
    • Entellus Medical (NASDAQ:ENTL) initiated with Buy rating and $22 (20% upside) price target by BTIG Research.
    • DENTSPLY SIRONA (NASDAQ:XRAY) initiated with Overweight rating and $70 (10% upside) price target by Piper Jaffray.
    | Fri, Jun. 17, 6:53 AM | 1 Comment
  • Fri, May 6, 8:58 AM
    • DENTSPLY (XRAY) Q1 results: Revenues: $772.6M (+17.7%); SG&A: $342.1M (+26.6%); Operating Income: $72.7M (-25.6%); Net Income: $125M (+95.3%); EPS: $0.70 (+55.6%); Non-GAAP EPS: $0.69 (+16.9%); Quick Assets: $323.1M (+13.5%); CF Ops: $0.7M (-98.9%).
    • 2016 Guidance: Adjusted EPS: $2.70 - 2.80.
    | Fri, May 6, 8:58 AM
  • Fri, May 6, 7:52 AM
    • DENTSPLY (NASDAQ:XRAY): Q1 EPS of $0.69 beats by $0.06.
    • Revenue of $772.6M (+17.7% Y/Y) beats by $37.85M.
    • Press Release
    | Fri, May 6, 7:52 AM
  • Thu, May 5, 5:30 PM
    | Thu, May 5, 5:30 PM | 5 Comments
  • Thu, Mar. 24, 4:05 PM
    • Accelerate Diagnostics (AXDX +12.7%) initiated with Overweight rating and $17 (26% upside) price target by JP Morgan.
    • Inogen (INGN -2.1%) initiated with Neutral rating with a $46 (15% upside) price target by Piper Jaffray.
    • Incyte (INCY +3.3%) initiated with Overweight rating and $85 (21% upside) price target by Morgan Stanley.
    • West Pharmaceutical Services (WST -0.1%) initiated with Outperform rating with a $69 (6% upside) price target by Wells Fargo.
    • Ironwood Pharmaceuticals (IRWD +1%) initiated with Neutral rating and $14 (35% upside) price target by Goldman Sachs.
    • HeartWare International (HTWR -0.4%) upgraded to Buy from Neutral by Bank of America.
    • WebMD (WBMD +0.4%) upgraded to 3.5 stars from 3.0 stars (out of 5.0) by top raters at Vetr community. Price target is $62.50 (7% upside).
    • Tandem Diabetes (TNDM -15.7%) downgraded to Underperform from Neutral by Bank of America.
    • EndoChoice (GI -9.1%) downgraded to Underperform from Buy with a $10 price target by Bank of America.
    • DENTSPLY (XRAY -1.6%) downgraded to Equal Weight from Overweight by Morgan Stanley. Price target is $65 (9% upside).
    • Novartis (NVS -0.8%) downgraded to Market Perform from Outperform by Leerink. Price target lowered to $85 (16% upside) from $98.
    • Infinity Pharmaceuticals (INFI -4.3%) downgraded to Underperform from Neutral by Wedbush. Price target lowered to $3 (40% downside risk) from $8.
    • Valeant Pharmaceuticals (VRX -7%) downgraded to Equal Weight with $34 (10% upside) price target by Barclays. Downgraded to Underperform from Neutral by Mizuho. Price target lowered to $18 (42% downside risk) from $70.
    | Thu, Mar. 24, 4:05 PM | 7 Comments
  • Mon, Feb. 29, 11:32 AM
    • The previously announced merger between Dentsply (XRAY +0.6%) and Sirona Dental Systems (SIRO) has been completed. Under the terms of the all-stock transaction, Sirona shareholders received 1.8142 shares of XRAY for each Sirona share. SIRO will cease trading today.
    • The combined company will do business as DENTSPLY SIRONA and will trade under the symbol "XRAY."
    • Previously: Dentsply and Sirona to merge (Sept. 15, 2015)
    | Mon, Feb. 29, 11:32 AM
  • Fri, Feb. 26, 3:58 PM
    • Achillion Pharmaceuticals (ACHN +7.4%) upgraded to Outperform from Neutral with a $10 (36% upside) price target by Baird
    • Insulet (PODD +8.5%) upgraded to Buy from Hold with a $40 (25% upside) price target by Benchmark.
    • DENTSPLY (XRAY -0.1%) upgraded to Neutral from Sell by UBS. Price target raised to $60 (1% downside risk) from $50.
    • PTC Therapeutics (PTCT -29.4%) upgraded Hold from Underperform by Jefferies. Price target lowered to $12 (22% upside) from $18.
    • AbbVie (ABBV -0.3%) upgraded to Buy from Neutral by Citigroup. Price target raised to $65 (16% upside) from $56.
    • Wellcare Health Plans (WCG +0.7%) upgraded to Overweight from Neutral by JP Morgan. Price target raised to $114 (24% upside) from $80.
    • Keryx Biopharmaceuticals (KERX +8.7%) downgraded to Neutral from Overweight by JP Morgan.
    • Peregrine Pharmaceuticals (PPHM -62.1%) downgraded to Neutral from Buy with a $0.50 (25% upside) price target by Roth Capital.
    • EXACT Sciences (EXAS -1.8%) downgraded to Neutral from Buy by Roth Capital and Equal Weight from Overweight by Stephens & Co.
    • Radius Health (RDUS -2.8%) downgraded to Hold from Buy with a $37 (23% upside) price target by Jefferies.
    • PTC Therapeutics (PTCT -29.4%) downgraded to Neutral from Buy by Citigroup. Price target lowered to $13 (56% upside) from $90.
    • Orexigen (OREX -31.9%) downgraded to Market Perform from Outperform by Leerink Swann. Price target lowered to $2 (104% upside) from $4.50.
    • Express Scripts (ESRX +2.4%) downgraded to Sell from Hold by Deutsche Bank. Price target lowered to $61(15% downside risk) from $93.
    • Perrigo (PRGO) downgraded to Sell from Neutral by Goldman Sachs. Price target lowered to $124 (4% downside risk) from $160.
    • Chimerix (CMRX -6.6%) downgraded to Neutral from Buy by Citigroup. Price target lowered to $9 (91% upside) from $13.
    | Fri, Feb. 26, 3:58 PM | 8 Comments
  • Fri, Feb. 26, 3:10 AM
    • PrivateBancorp (NASDAQ:PVTB) will replace Sirona Dental Systems (NASDAQ:SIRO) in the S&P MidCap 400.
    • Cogent Communications (NASDAQ:CCOI) will replace PrivateBancorp in the S&P SmallCap 600
    • Both will occur after the close of trading on Monday, February 29.4
    • Dentsply (NASDAQ:XRAY) is acquiring Sirona in a deal expected to be completed on or about that date. Dentsply (soon to be Dentsply Sirona) is an S&P 500 component.
    | Fri, Feb. 26, 3:10 AM
  • Fri, Feb. 12, 7:52 AM
    • DENTSPLY (XRAY -2.1%) Q4 results: Revenues: $671.1M (-6.7%); SG&A: $267.8M (-5.5%); Operating Income: $93.1M (-9.9%); Net Income: $58.6M (-30.8%); EPS: $0.41 (-30.5%); Non-GAAP EPS: $0.65 (+8.3%).
    • FY2015 results: Revenues: $2,674.3M (-8.5%); SG&A: $1,077.3M (-5.8%); Operating Income: $375.2M (-15.8%); Net Income: $251.2M (-22.2%); EPS: $1.76 (-21.4%); Non-GAAP EPS: $2.62 (+4.8%); Quick Assets: $284.6M (+87.7%).
    • No guidance given.
    | Fri, Feb. 12, 7:52 AM
  • Fri, Feb. 12, 7:23 AM
    • DENTSPLY (NASDAQ:XRAY): Q4 EPS of $0.65 in-line.
    • Revenue of $671.1M (-6.7% Y/Y) misses by $18.27M.
    | Fri, Feb. 12, 7:23 AM
  • Thu, Feb. 11, 5:30 PM
    | Thu, Feb. 11, 5:30 PM | 1 Comment
  • Oct. 28, 2015, 10:14 AM
    • DENTSPLY (XRAY -0.8%) Q3 results: Revenues: $648.9M (-8.4%); COGS: $279.4M (-12.7%); SG&A: $264.3M (-4.2%); Operating Income: $98.6M (-10.0%); Net Income: $84.5M (+12.2%); EPS: $0.59 (+13.5%); Quick Assets: $236.4M (+55.8%); CF Ops: $371M (+0.9%).
    • 2015 Guidance: Adjusted EPS: $2.58 - 2.64.
    | Oct. 28, 2015, 10:14 AM
  • Oct. 28, 2015, 7:50 AM
    • DENTSPLY (NASDAQ:XRAY): Q3 EPS of $0.66 beats by $0.03.
    • Revenue of $648.9M (-8.4% Y/Y) misses by $18.06M.
    | Oct. 28, 2015, 7:50 AM
Company Description
DENTSPLY SIRONA, Inc. is a manufacturer of professional dental products and technologies. It develops, manufactures and markets general dental supplies, Computer Aided Design/Computer Aided Manufacturing restoration systems, Ceramic ReConstruction (CERE), a full suite of dental restorative... More
Sector: Healthcare
Industry: Medical Instruments & Supplies
Country: United States